STC101

About STC Biologics

STC Biologics is a private, revenue-generating CDMO specializing in biologics development services. Its key differentiator is a holistic, integrated approach that combines deep expertise in biology, process development, analytics, and regulatory sciences within a single, cross-functional team, aimed at accelerating client timelines to the clinic. The company leverages its proprietary Speed-To-Clinic Platform™ for monoclonal antibodies and boasts a management team with extensive experience in global regulatory filings, having contributed to over 8 BLAs and dozens of INDs. While primarily a service provider, STC also has an internal biosimilar program, STC101, currently in clinical development in Europe.